Stoke Therapeutics Insider: Option Exercises at $7.07, Sales Under 10b5-1 Plan
Rhea-AI Filing Summary
Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics (STOK), reported multiple option exercises and open-market sales in late August and early September 2025. He exercised stock options at an exercise price of $7.07 on 08/29/2025 (850 shares) and 09/02/2025 (9,150 shares), and sold common stock in multiple transactions: 850 shares on 08/29/2025 at $20.00, 14,922 shares on 09/02/2025 at a weighted average $20.1375, and 6,345 shares on 09/03/2025 at a weighted average $20.0657. The filings state the sales were executed pursuant to a Rule 10b5-1 trading plan adopted 12/12/2024. After these transactions, the reporting person beneficially owned 11,831 shares of common stock and retained outstanding options covering additional shares.
Positive
- Sales executed under a Rule 10b5-1 trading plan, adopted 12/12/2024, indicating a pre-established, documented process for transactions
- Option exercises at $7.07 demonstrate conversion of in-the-money awards into shares rather than cashless exercises
- Filer retains equity: the Form 4 shows remaining beneficial ownership and outstanding option positions after transactions
Negative
- Significant share sales (totaling 21, unaggregated: 22,117 shares sold across dates) reduced the reporting person’s direct common stock position to 11,831 shares
- Large disposals at market prices (~$20.00–$20.40) materially monetized previously granted equity, which may reduce insider ownership concentration
Insights
TL;DR: Routine option exercises followed by scheduled sales under a 10b5-1 plan; neutral signaling absent other material facts.
The Form 4 shows exercise of options at $7.07 and subsequent open-market sales at roughly $20 per share under a pre-existing Rule 10b5-1 plan. These are standard executive liquidity events: the reporter converted in-the-money options and sold portions of the resulting shares in multiple tranches. The filing discloses weighted-average sale prices and confirms the 10b5-1 plan adoption date, improving compliance transparency. The reporter retains some equity through remaining common shares and unexercised/vested option positions disclosed in the derivative table.
TL;DR: Transactions documented and executed under an established 10b5-1 plan, indicating procedural compliance.
The disclosure identifies the reporting person as General Counsel and Corporate Secretary and marks sales as pursuant to a Rule 10b5-1 plan adopted 12/12/2024. Using a trading plan reduces the risk of insider trading concerns if the plan was implemented while not in possession of material nonpublic information. The Form 4 includes full option vesting language and provides weighted-average sale prices with an undertaking to supply detailed per-trade breakdowns upon request, which supports regulatory transparency.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,345 | $20.0657 | $127K |
| Exercise | Stock Option (Right to Buy) | 9,150 | $0.00 | -- |
| Exercise | Common Stock | 9,150 | $7.07 | $65K |
| Sale | Common Stock | 14,922 | $20.1375 | $300K |
| Exercise | Stock Option (Right to Buy) | 850 | $0.00 | -- |
| Exercise | Common Stock | 850 | $7.07 | $6K |
| Sale | Common Stock | 850 | $20.00 | $17K |
Footnotes (1)
- This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.20, inclusive. The option vested or vests as to 1/48th of the total award on January 7, 2023, with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
